TYK-00540

DRUG3 trials

Sponsors

TYK Medicines, Inc

Conditions

HR-positive, HER2-negative Advanced Breast CancerLocally Advanced or Metastatic Solid TumorsmCRPC

Phase 1

A Study of TYK-00540 in Adult Patients With Solid Tumors

RecruitingNCT06246071

TYK Medicines, IncLocally Advanced or Metastatic Solid Tumors

Start: 2024-01-02End: 2026-12-05Target: 156Updated: 2024-02-07

Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

RecruitingNCT06950086

TYK Medicines, IncHR-positive, HER2-negative Advanced Breast Cancer

Start: 2024-01-02End: 2026-11-30Target: 180Updated: 2025-04-29

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

Not yet recruitingNCT07104643

TYK Medicines, IncmCRPC

Start: 2025-08-31End: 2026-11-30Target: 48Updated: 2025-08-05